New polymorphic form of 1- (4- { l- [ (E) - 4-cyclohexyl--3-trifluoromethyl-benzylox yimino] -ethyl) -2-ethyl-benzy l) - azetidine-3-carboxylic

Details for Australian Patent Application No. 2009327405 (hide)

Owner Novartis AG

Inventors Liu, Yugang; Papoutsakis, Dimitris; Roddy, Elizabeth

Agent Davies Collison Cave

Pub. Number AU-A-2009327405

PCT Pub. Number WO2010/071794

Priority 61/203,052 18.12.08 US

Filing date 17 December 2009

Wipo publication date 24 June 2010

International Classifications

C07D 205/04 (2006.01) Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61P 21/00 (2006.01) Drugs for disorders of the muscular or neuromuscular system

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 31/06 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 31/08 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

30 June 2011 PCT application entered the National Phase

  PCT publication WO2010/071794 Priority application(s): WO2010/071794

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009327407-Method and apparatus for performing remote calibration verification

2009327387-Organosolv and ozone treatment of biomass to enhance enzymatic saccharification